Executive Summary
The India BSE Pharma stream on 2026-10-30 is dominated by Q2 FY27 earnings, with 13 new filings across Max Healthcare, Mankind, Sun Pharma, Cipla, Alkem and Zydus.
A clear sector pattern is emerging: revenue growth is healthy (Max +20.3% YoY, Mankind +17.3%, Sun +11.9%, Cipla +4% QoQ) but profit quality is diverging sharply due to one-offs, tax effects and margin pressure. Max Healthcare's consolidated PAT fell 15.6% YoY despite 20.3% revenue growth, as expenses rose 20.1% and finance costs jumped 37%; H1 PAT growth of 7% lagged H1 revenue growth of 18%. Sun Pharma's PAT collapsed 36.2% YoY on ₹12,688.3 Million exceptional items, though pre-exceptional PBT rose 6.3%. Mankind stands out with EBITDA +27.2% and PAT +37.7%, aided by 33% international growth and improving volume trajectory (6.2% in Q2 vs 0.5% in FY25). Cipla showed sequential margin recovery (+200 bps QoQ to 18.7%) but faces a US FDA Form 483 with 7 observations at Pithampur. Regulatory news was mixed: Alkem's Mandva API facility received a clean US FDA inspection (no Form 483), while Sun Pharma won US FDA approval for ILUMYA in psoriatic arthritis. Capital allocation remains growth-heavy: Max approved ₹415 Cr capex for 209 brownfield beds and revised its Gurugram project cost upward to ₹1,143 Cr with completion delayed to April 2027. Insider/ESOP activity was routine and non-material (Max allotted 16,803 shares at ₹350 and granted 95,000 options at ₹800). Overall, the sector shows top-line resilience but earnings quality and margin sustainability are key differentiators; we flag Max's margin compression and Sun's exceptional-item volatility as near-term risks while highlighting Mankind's volume-led beat and Cipla's margin recovery as opportunities.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Corporate governance
Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from October 23, 2026.
Investment Signals (12)
- Mankind Pharma ↓ (BULLISH)▲
Revenue +17.3% YoY to ₹4,338 Cr, EBITDA +27.2% to ₹1,175 Cr, PAT +37.7% to ₹716 Cr; volume growth accelerated to 6.2% in Q2 FY27 from 0.5% in FY25 and 4.7% in Q1; international revenue +33% to ₹680 Cr; chronic share ex-BSV up 80 bps to 37.4%
- Sun Pharmaceutical ↓ (BULLISH)▲
Pre-exceptional PBT +6.3% YoY to ₹44,282 Mn and standalone revenue +35% YoY to ₹61,419 Mn; US FDA approved ILUMYA sBLA for psoriatic arthritis, expanding label beyond psoriasis
- Cipla ↓ (BULLISH)▲
EBITDA margin ex-other income expanded 200 bps QoQ to 18.7%; India business +12% YoY led by branded prescription +15%; North America revenue rose $10 Mn QoQ to $172 Mn
- Alkem Laboratories ↓ (BULLISH)▲
US FDA inspection at Mandva API facility concluded with zero Form 483 observations, a clean regulatory outcome that supports uninterrupted API supply
- Max Healthcare ↓ (BULLISH)▲
Network gross revenue +20% YoY and +8% QoQ to ₹3,219 Cr; PAT +26% QoQ to ₹448 Cr; ARPP improved to ₹2.31 lakh from ₹2.14 lakh YoY; free cash from operations doubled to ₹500 Cr vs ₹291 Cr in Q2 FY26
- Max Healthcare ↓ (BULLISH)▲
Kalinga Hospital stake raised from 58.28% to 66.34%, consolidating ownership; Max Lab revenue +24% YoY to ₹66 Cr across 63+ cities
- Sun Pharmaceutical ↓ (NEUTRAL)▲
Board appointed Deloitte Haskins & Sells as statutory auditor for five years, ensuring continuity post S R B C & CO rotation
- Mankind Pharma ↓ (BULLISH)▲
Acquired Armed Cell Therapeutics for €48 Mn and received PRIP funding for JAK inhibitor, adding pipeline optionality
- Max Healthcare ↓ (BULLISH)▲
Board approved ₹415 Cr capex for 209 brownfield beds and ₹93 Cr for MSSH Noida redevelopment, signaling continued bed-capacity expansion
- Cipla ↓ (NEUTRAL)▲
PAT at ₹878 Cr (11.9% of sales) with revenue +4% QoQ to ₹7,404 Cr; EMEU revenue at $101 Mn
- Zydus Lifesciences ↓ (NEUTRAL)▲
Routine duplicate share certificate notice for 3,000 shares; no financial impact
- Max Healthcare ↓ (NEUTRAL)▲
ESOP allotment of 16,803 shares at ₹350 and grant of 95,000 options at ₹800; negligible dilution (~0.000017%)
Risk Flags (10)
- Max Healthcare↓ [HIGH RISK]▼
Consolidated PAT fell 15.6% YoY to ₹41,445 Lakh despite revenue +20.3%; total expenses rose 20.1% YoY, outpacing revenue; professional fees +24.6% and finance costs +37% YoY; H1 PAT growth of 7% lagged H1 revenue growth of 18%
- Sun Pharmaceutical↓ [HIGH RISK]▼
PAT plunged 36.2% YoY to ₹19,885.3 Mn due to ₹12,688.3 Mn exceptional items; EPS fell to ₹8.3 from ₹13.0; R&D spend declined QoQ to ₹7,470 Mn from ₹8,076.6 Mn, which could pressure future pipeline
- Cipla↓ [HIGH RISK]▼
US FDA issued 7 observations in Form 483 for the Pithampur facility; resolution pending, creating regulatory overhang
- Max Healthcare↓ [MEDIUM RISK]▼
Operating EBITDA margin slipped to 26.8% from 26.9% YoY; net debt rose to ₹2,369 Cr from ₹2,067 Cr a year ago; Gurugram project cost revised upward to ₹1,143 Cr with completion delayed to April 2027
- Mankind Pharma↓ [MEDIUM RISK]▼
Consumer healthcare revenue at ₹229 Cr, impacted by slower category offtake; growth slowed to 2.6% in H1 FY27 vs 9% in FY26 and 15% in FY25; full-year growth expected in single digits
- Cipla↓ [MEDIUM RISK]▼
Trade generics grew only mid-single digits YoY; South Africa declined due to accounting change and lost tender, though a favorable court ruling may correct it
- Max Healthcare↓ [MEDIUM RISK]▼
Professional and consultancy fee jumped 24.6% YoY to ₹56,413 Lakh, contributing to margin pressure; finance costs up 37% YoY
- Sun Pharmaceutical↓ [MEDIUM RISK]▼
Consolidated H1 PAT declined 9.5% YoY to ₹48,833.2 Mn; employee benefits expense +18.4% YoY, outpacing revenue growth
- Max Healthcare↓ [LOW RISK]▼
ESOP grant at ₹800 exercise price (vs ₹350 for prior allotment) could indicate rising compensation costs, though non-material now
- Zydus Lifesciences↓ [LOW RISK]▼
Shareholder loss of 3,000 share certificates is routine but highlights administrative processes; no financial impact
Opportunities (10)
- Mankind Pharma↓ (OPPORTUNITY)◆
Volume-led growth acceleration (6.2% in Q2 vs 0.5% in FY25) and 33% international growth provide earnings visibility; PAT +37.7% YoY with EBITDA margin expansion; potential re-rating if volume trajectory sustains
- Sun Pharmaceutical↓ (OPPORTUNITY)◆
ILUMYA label expansion into psoriatic arthritis opens additional US market; IL-23 inhibitor with no new safety signals; commercial impact not yet quantified, creating upside surprise potential
- Cipla↓ (OPPORTUNITY)◆
EBITDA margin recovery of 200 bps QoQ to 18.7% and India business +12% YoY; if Pithampur Form 483 is resolved favorably, regulatory overhang could lift
- Alkem Laboratories↓ (OPPORTUNITY)◆
Clean US FDA inspection at Mandva API facility with zero Form 483 observations; reduces regulatory risk and supports API supply continuity
- Max Healthcare↓ (OPPORTUNITY)◆
Bed capacity expansion (209 brownfield beds, ₹415 Cr capex) and Kalinga stake increase to 66.34% set up future revenue growth; ARPP up 8% YoY to ₹2.31 lakh; free cash flow doubled to ₹500 Cr
- Max Healthcare↓ (OPPORTUNITY)◆
Max Lab revenue +24% YoY to ₹66 Cr with 2,700+ tests across 63+ cities; diagnostics business scaling could add diversification
- Mankind Pharma↓ (OPPORTUNITY)◆
Acquisition of Armed Cell Therapeutics for €48 Mn and PRIP funding for JAK inhibitor add pipeline; potential for future product launches
- Sun Pharmaceutical↓ (OPPORTUNITY)◆
Standalone revenue +35% YoY to ₹61,419 Mn and standalone PAT +54% YoY to ₹8,712.9 Mn, showing strong India/emerging market performance
- Cipla↓ (OPPORTUNITY)◆
North America revenue rose $10 Mn QoQ to $172 Mn; EMEU at $101 Mn; sequential improvement in key markets
- Max Healthcare↓ (OPPORTUNITY)◆
International patient revenue at ₹307 Cr (~10% of hospital revenue) provides growth cushion; H1 revenue +18.6% to ₹4,93,538 Lakh
Sector Themes (6)
- Revenue Growth vs Profit Quality Divergence◆
Across 4 major pharma/hospital companies, revenue growth was strong (Max +20.3% YoY, Mankind +17.3%, Sun +11.9%, Cipla +4% QoQ) but PAT trends diverged sharply (Mankind +37.7%, Max -15.6%, Sun -36.2%) due to one-offs, tax effects and margin pressure. Investors should focus on pre-exceptional earnings and operating metrics.
- Margin Pressure from Cost Inflation◆
Max Healthcare saw total expenses rise 20.1% YoY, outpacing revenue, with professional fees +24.6% and finance costs +37%; Sun Pharma's employee benefits +18.4% YoY also outpaced revenue. Cost inflation is a sector-wide watch item.
- Regulatory Mixed Bag◆
Alkem received a clean US FDA inspection (zero Form 483), while Cipla received 7 observations at Pithampur; Sun Pharma won a US FDA label expansion for ILUMYA. Regulatory outcomes are a key stock-specific driver.
- Capital Allocation Towards Capacity Expansion◆
Max Healthcare approved ₹415 Cr capex for 209 beds and revised Gurugram project cost to ₹1,143 Cr; Mankind acquired Armed Cell Therapeutics for €48 Mn. Growth capex is prioritized over shareholder returns, with Max's dividend at only ₹2/share.
- Volume Recovery in Domestic Formulations◆
Mankind's volume growth improved from 0.5% in FY25 to 6.2% in Q2 FY27; Cipla's India business grew 12% YoY led by branded prescription +15%. Domestic market momentum is building.
- ESOP Activity Routine◆
Max Healthcare's ESOP allotment (16,803 shares at ₹350) and grant (95,000 options at ₹800) are non-material; no significant insider buying or selling was reported across filings.
Watch List (8)
-
Q2 FY27 earnings call and management commentary on margin trajectory; watch for further details on Gurugram project delay and cost overrun; next board meeting for Q3 FY27 results (date TBD).
-
Earnings call recording available; watch for management commentary on exceptional items and R&D spend decline; ILUMYA psoriatic arthritis launch metrics in subsequent quarters.
- 👁
US FDA Form 483 with 7 observations at Pithampur; watch for remediation updates and potential re-inspection; management commentary on South Africa tender loss and court ruling.
-
Consumer healthcare growth guidance of single digits for FY27; watch for recovery in category offtake and integration of Armed Cell Therapeutics.
-
Clean US FDA inspection at Mandva; watch for any follow-up inspections or ANDA approvals from the facility.
-
ESOP grant at ₹800 exercise price; watch for any insider transactions or further ESOP grants that could signal management confidence.
-
Duplicate share certificate issuance after 7-day objection window; no financial impact but monitor for any shareholder disputes.
- Sector👁
Upcoming Q3 FY27 earnings season and any US FDA inspections across the sector; watch for margin trends and cost inflation commentary.
Filing Analyses
(15)
30-10-2026
Max Healthcare reported Q2 FY27 network gross revenue of ₹ 3,219 Cr, up 20% YoY and 8% QoQ, driven by higher OBDs (+13% YoY), with PAT at ₹ 448 Cr (+10% YoY, +26% QoQ). However, operating EBITDA margin dipped slightly to 26.8% from 26.9% YoY, and H1 PAT growth of 7% (₹ 805 Cr) lagged H1 revenue growth of 18% (₹ 6,200 Cr), indicating margin pressure. Net debt rose to ₹ 2,369 Cr from ₹ 2,067 Cr a year ago, while free cash from operations improved sharply to ₹ 500 Cr versus ₹ 291 Cr in Q2 FY26.
- · Kalinga Hospital Limited stake increased from ~58.28% to ~66.34% as on September 7, 2026
- · MSSH Dwarka Oncology Block to enable main hospital to reach 318 beds in Q3 FY27
- · Max Lab services available across 63+ cities with over 2,700+ tests
- · International patient revenue accounts for ~10% of hospital revenue
- · ~4,978 liver transplants, ~6,329 kidney transplants and ~2,348 bone marrow transplants performed till date
- · 130 clinical trials and 25 grant studies ongoing; ~155 clinical research projects ongoing
- · 610+ MBBS doctors in DNB programmes across 40+ specialities
- · Network operates 21 healthcare facilities (~6,200 beds) with significant North India presence
- · H1 FY27 cash from operations was ₹ 897 Cr
30-10-2026
Max Healthcare's board approved unaudited consolidated results for Q2/H1 FY27, with revenue from operations rising 20.3% YoY to ₹2,56,921 Lakh (from ₹2,13,547 Lakh) and profit for the period declining 15.6% YoY to ₹41,445 Lakh (from ₹49,130 Lakh) due to a sharply higher tax expense of ₹12,647 Lakh versus ₹14,527 Lakh prior year and higher costs. The board also approved capex of ~₹93 Crore for MSSH Noida redevelopment, ~₹97 Crore for additional floors at MSSH Vaishali, and revised the ~525-bed Gurugram (Sector-56) project cost upward to ~₹1,143 Crore with completion pushed to April 2027. Dr. Dharmender Kumar was appointed Director & Chief - Public Affairs (SMP) effective November 1, 2026.
- · Total expenses rose to ₹2,06,919 Lakh in Q2 FY27 from ₹1,72,234 Lakh in Q2 FY26
- · Employee benefits expense increased to ₹39,931 Lakh from ₹33,832 Lakh YoY
- · Professional and consultancy fee rose to ₹56,413 Lakh from ₹45,273 Lakh YoY
- · Finance costs increased to ₹7,384 Lakh from ₹5,392 Lakh YoY
- · Depreciation and amortization rose to ₹13,763 Lakh from ₹10,810 Lakh YoY
- · Basic EPS declined to ₹4.26 in Q2 FY27 from ₹5.05 in Q2 FY26; H1 basic EPS ₹7.58 vs ₹8.22
- · Two unreviewed subsidiaries reported net loss after tax of ₹(532) Lakh for the quarter and ₹(862) Lakh for the period
- · MHC Global Healthcare (Nigeria) Limited liquidated w.e.f. October 28, 2026
- · Kalinga Hospital Limited and Yerawada Properties Private Limited added as subsidiaries w.e.f. May 18, 2026 and June 30, 2026 respectively
- · Board meeting commenced at 12.50 pm and concluded at 2.35 pm IST on October 30, 2026
30-10-2026
Max Healthcare reported Q2 FY27 network gross revenue of ₹ 3,219 Cr, up 20% YoY and 8% QoQ, driven by higher occupied bed days, with network PAT at ₹ 448 Cr (+10% YoY, +26% QoQ). However, operating EBITDA margin slipped to 26.8% from 26.9% YoY, and H1 PAT growth of 7% (₹ 805 Cr) lagged H1 revenue growth of 18% (₹ 6,200 Cr), indicating margin pressure. The Board approved ₹ 415 Cr capex for 209 brownfield beds, and net debt was broadly flat at ₹ 2,369 Cr versus ₹ 2,384 Cr in the prior quarter.
- · ARPP for Q2 FY27 was ₹ 2.31 lakh versus ₹ 2.14 lakh in Q2 FY26 and ₹ 2.30 lakh in Q1 FY27
- · International patient revenue of ₹ 307 Cr accounted for ~10% of hospital revenue
- · Max Lab revenue of ₹ 66 Cr grew 24% YoY and 15% QoQ across 63+ cities with 2,700+ tests
- · Max@Home revenue of ₹ 86 Cr grew 37% YoY and 10% QoQ
- · Shareholding in Kalinga Hospital Limited rose from ~58.28% to ~66.34% as on September 7, 2026
- · Net debt rose to ₹ 2,369 Cr from ₹ 2,067 Cr a year earlier (Sep 2025)
- · Capex breakdown: 85 beds at MSSH Noida, 60 beds at MSSH Vaishali, 64 beds at BLK Max
- · MSSH Dwarka Oncology Block to take main hospital to 318 beds during Q3 FY27
- · Clinical: ~4,978 liver, ~6,329 kidney and ~2,348 bone marrow transplants performed till date
- · Research: 900+ clinical research projects completed, ~155 ongoing; 610+ MBBS doctors in DNB programmes across 40+ specialities
30-10-2026
Mankind Pharma reported Q2 FY27 revenue of Rs. 4,338 crore, up 17.3% YoY, with EBITDA up 27.2% to Rs. 1,175 crore and PAT up 37.7% to Rs. 716 crore. Domestic business grew 14.8% to Rs. 3,657 crore, while international revenue surged 33% to Rs. 680 crore. However, consumer healthcare revenue was Rs. 229 crore, impacted by slower category offtake and regional issues, with full-year growth expected in single digits. The company announced the acquisition of Armed Cell Therapeutics for €48 million and received PRIP funding for its JAK inhibitor.
- · Volume growth improved from 0.5% in FY25 to 2.3% in FY26, 4.7% in Q1 FY27, and 6.2% in Q2 FY27.
- · Chronic share excluding BSV expanded by 80 bps YoY to 37.4%.
- · Consumer healthcare growth slowed to 2.6% in H1 FY27 vs 9% in FY26 and 15% in FY25.
- · Net debt to adjusted EBITDA ratio at 0.6x; net debt Rs. 2,639 crore.
- · Effective tax rate rose to 24% in H1 FY27 from 17.1% in H1 FY26 due to new tax regime.
- · R&D expenses at 2.5% of sales in Q2 FY27, lower than guidance of 3% for FY27.
- · Cash flow to EBITDA ratio declined to 81% in H1 FY27 from 92% in H1 FY26 due to increased working capital.
- · Net working capital days increased to 51 days from 46 days YoY.
- · CAPEX for H1 FY27 was Rs. 214 crore, 4.9% of revenue, below guidance of 6-7%.
- · Armed Cell Therapeutics acquisition commitment of €48 million, funded up to FY28.
- · Tax disallowance under Section 37(1) of Rs. 1,609 crore; favorable order from Commissioner of Appeals reduced exposure by Rs. 300 crore.
- · Field force productivity improved to Rs. 7.4 lakhs (TTM) from Rs. 7 lakhs last year.
- · Hospital revenue grew 23% YoY.
- · Modern trade and e-commerce share increased to 18% from 12% a year ago, with 55% growth.
- · BSV grew 34%, Mankind US 29%, other international markets 37%.
- · Anti-infective growth improved to 5.4% in Q2 FY27 from 3.6% in Q1 FY27.
- · 9 new brand families with sales over Rs. 50 crore added, total 63 vs 54 in FY26; 4 new brand families with sales over Rs. 100 crore added, total 26 vs 22.
- · EBITDA margin guidance maintained at 25.5-26.5% for FY27.
- · R&D guidance for FY27 expected at upper end of 2.8-3% of revenue.
- · MR addition guidance of ~7% for FY27 on track.
30-10-2026
Max Healthcare Institute Limited reported consolidated revenue from operations of ₹2,56,921 Lakh for Q2 FY27, up 20.3% YoY from ₹2,13,547 Lakh, while consolidated profit for the period declined 15.6% YoY to ₹41,445 Lakh from ₹49,130 Lakh — the prior-year quarter benefited from a one-time tax reversal of ₹7,939 Lakh tied to the Crosslay Remedies merger. On a sequential basis revenue rose 8.6% (from ₹2,36,617 Lakh) and PAT rose 28.3% (from ₹32,296 Lakh). The quarter included acquisitions of Kalinga Hospital Ltd (58.28% stake for ₹29,797 Lakh, raised to 66.34%) and Yerawada Properties Private Limited (₹8,792 Lakh), plus a final dividend of ₹2 per share paid August 11, 2026.
- · Total expenses rose 20.1% YoY to ₹2,06,919 Lakh in Q2 FY27 from ₹1,72,234 Lakh, outpacing revenue growth of 20.3% only marginally.
- · Professional and consultancy fee jumped 24.6% YoY to ₹56,413 Lakh (Q2 FY27) from ₹45,273 Lakh.
- · Employee benefits expense grew 18.0% YoY to ₹39,931 Lakh; finance costs rose 37.0% YoY to ₹7,384 Lakh.
- · Two unreviewed subsidiaries reported nil revenue and net losses of ₹(532) Lakh for the quarter and ₹(862) Lakh for the half-year; management states these are not material to the Group.
- · Kalinga Hospital Ltd acquisition (58.28% for ₹29,797 Lakh, May 18, 2026) generated provisional goodwill of ₹20,096 Lakh; stake raised to 66.34% via rights issue of ₹8,787 Lakh.
- · Yerawada Properties Private Limited (1.68-acre land parcel in central Pune) acquired for ₹8,792 Lakh on June 30, 2026, accounted as an asset acquisition.
- · MHC Global Healthcare (Nigeria) Limited completed members' voluntary winding-up on October 28, 2026, with no material impact.
- · Consolidated cash and cash equivalents fell to ₹55,671 Lakh from ₹66,580 Lakh at March 31, 2026, a net decrease of ₹10,914 Lakh for H1 FY27.
- · Trade receivables rose to ₹1,24,336 Lakh from ₹96,975 Lakh at March 31, 2026.
- · Total borrowings (current + non-current) increased to ₹3,20,956 Lakh from ₹2,90,682 Lakh at March 31, 2026.
- · Statutory auditors S.R. Batliboi & Co. LLP issued an unmodified limited review report; results approved by the Board on October 30, 2026.
- · The Group operates in a single reportable segment: Medical and Healthcare Services, in India.
30-10-2026
Sun Pharmaceutical Industries reported consolidated revenue from operations of ₹161,987.1 Million for Q2 FY27 (quarter ended 30.09.2026), up 11.9% YoY from ₹144,783.1 Million, while net profit after taxes fell 36.2% YoY to ₹19,885.3 Million from ₹31,179.5 Million, largely due to exceptional items of ₹12,688.3 Million in the current quarter versus none in the prior-year quarter. Profit before exceptional items and tax rose 6.3% YoY to ₹44,282.0 Million, but basic and diluted EPS declined to ₹8.3 from ₹13.0. On a sequential basis, revenue grew 5.9% QoQ from ₹152,998.8 Million, however PAT dropped 31.3% QoQ from ₹28,947.9 Million, and R&D spend declined to ₹7,470.0 Million from ₹8,076.6 Million QoQ and ₹7,680.6 Million YoY.
- · Standalone (parent) revenue from operations was ₹61,419.2 Million for Q2 FY27 versus ₹45,481.1 Million in Q2 FY26, with standalone PAT of ₹8,712.9 Million versus ₹5,642.2 Million.
- · Consolidated half-year revenue from operations rose 11.2% to ₹314,985.9 Million (H1 FY27) from ₹283,297.1 Million (H1 FY26), while half-year PAT declined 9.5% to ₹48,833.2 Million from ₹53,965.8 Million.
- · Consolidated employee benefits expense increased 18.4% YoY to ₹32,741.6 Million from ₹27,647.9 Million.
- · Consolidated finance costs declined to ₹746.7 Million from ₹998.6 Million YoY.
- · Net gain on foreign currency transactions was ₹784.6 Million in Q2 FY27 versus ₹4,304.7 Million in Q2 FY26.
- · Total comprehensive income attributable to owners of the Company fell to ₹25,011.3 Million from ₹45,254.0 Million YoY.
- · Other equity stood at ₹833,301.6 Million as of 31.03.2026 (audited).
30-10-2026
Max Healthcare Institute Limited reported Q2 FY27 consolidated revenue from operations of ₹2,56,921 Lakh, up 20.3% YoY from ₹2,13,547 Lakh, while consolidated profit for the period declined 15.6% YoY to ₹41,445 Lakh from ₹49,130 Lakh (prior year benefited from a tax reversal of ₹7,939 Lakh). Half-year revenue rose 18.6% to ₹4,93,538 Lakh and H1 PAT fell 7.7% to ₹73,741 Lakh, with EBITDA-level profitability supported by a 20.0% rise in pre-exceptional PBT to ₹54,092 Lakh. The company also completed acquisitions of Kalinga Hospital (58.28% stake for ₹29,797 Lakh, raised to 66.34%) and Yerawada Properties (₹8,792 Lakh), and approved a final dividend of ₹2 per share.
- · Total expenses rose 20.1% YoY to ₹2,06,919 Lakh in Q2 FY27 from ₹1,72,234 Lakh, outpacing revenue growth and compressing margins.
- · Employee benefits expense increased 18.0% YoY to ₹39,931 Lakh; professional and consultancy fee rose 24.6% to ₹56,413 Lakh.
- · Finance costs jumped 37.0% YoY to ₹7,384 Lakh from ₹5,392 Lakh.
- · Q2 FY26 PAT included a tax reversal benefit of ₹7,939 Lakh (current tax) and ₹6,977 Lakh (net deferred tax credit) from the Crosslay Remedies merger, making the YoY PAT comparison unfavourable.
- · Standalone revenue from operations grew 14.3% YoY to ₹84,197 Lakh; standalone PAT rose 4.9% to ₹16,833 Lakh.
- · Cash and cash equivalents declined to ₹55,671 Lakh as of September 30, 2026 from ₹66,580 Lakh at March 31, 2026.
- · Total borrowings (non-current + current) rose to ₹3,20,956 Lakh from ₹2,90,682 Lakh at March 31, 2026.
- · MHC Global Healthcare (Nigeria) Limited completed voluntary winding-up effective October 28, 2026, with no material impact.
- · Kalinga Hospital is a 250-bed NABH-accredited multi-specialty hospital in Bhubaneswar, Odisha; provisional goodwill of ₹20,096 Lakh recognized.
- · Yerawada Properties owns a 1.68-acre land parcel in central Pune.
30-10-2026
Zydus Lifesciences Limited published a newspaper notice on October 30, 2026 (in Financial Express English and Gujarati editions) informing that a shareholder, Shivanand Patel (Folio No. 057043, Certificate No. 2177820, Distinctive Nos. 2174821–2177820), has reported loss/misplacement of share certificates covering 3,000 equity shares. If no objection is received within 7 days of publication, the Company will issue duplicate share certificates. This is a routine administrative/shareholder-servicing disclosure with no financial or operational impact on the company.
- · Notice published in Financial Express English and Gujarati editions on October 30, 2026
- · Shareholder folio number: 057043; certificate number: 2177820
- · Distinctive numbers of shares: 2174821 to 2177820
- · Notice dated October 29, 2026, signed at Ahmedabad
- · Company CIN: L24230GJ1951PLC025171
- · BSE listing code 532321; NSE symbol Zyduslife
30-10-2026
Max Healthcare Institute Limited allotted 16,803 fully paid-up equity shares of face value ₹10 each to eligible employees on October 30, 2026, following exercise of vested options under the Max Healthcare Institute Limited - Employee Stock Option Scheme 2022, at an exercise price of ₹350 per share (premium of ₹340 per share). Post-allotment paid-up equity share capital rose marginally to ₹973,32,70,540 from ₹973,31,02,510, with total shares outstanding increasing to 97,33,27,054 from 97,33,10,251. The company explicitly stated the allotment is not material under Regulation 30 of SEBI LODR, and the dilution impact is negligible (approximately 0.000017% of the pre-allotment share base).
- · Distinctive numbers of newly allotted shares range from 97,33,10,252 to 97,33,27,054 (both inclusive)
- · Shares issued in dematerialized form under ISIN INE027H01010; no share certificates applicable
- · No lock-in applicable on the allotted shares
- · Shares are identical in all respects to existing equity shares
- · Nomination & Remuneration Committee meeting commenced at 10.31 am IST and concluded at 10.48 am IST on October 30, 2026
- · Original ESOP scheme statement was filed with exchanges on September 29, 2022 (BSE ref: DCS/IPO/MJ/ESOP-IP/2511/2022-23; NSE ref: NSE/LIST/32765)
- · Company stated the allotment is not material in nature under Regulation 30 of SEBI LODR, 2015
- · Registered office: 401, 4th Floor, Man Excellenza, S. V. Road, Vile Parle (West), Mumbai - 400 056, Maharashtra
30-10-2026
Sun Pharmaceutical Industries Limited announced that its Board, at its meeting held on 30 October 2026, approved the appointment of Deloitte Haskins & Sells Chartered Accountants LLP (Firm Registration No. 117364W/W100739) as Statutory Auditors for five consecutive years, subject to shareholder approval. The change follows the mandatory auditor rotation under Section 139(2) of the Companies Act, 2013, as existing auditors S R B C & CO LLP complete their second consecutive five-year term at the conclusion of the FY2026-27 AGM. The new auditor's term runs from the conclusion of the FY2026-27 AGM until the conclusion of the FY2031-32 AGM.
- · Board meeting commenced at 10:45 AM (IST) and concluded at 02:55 PM (IST) on 30 October 2026
- · Deloitte Haskins & Sells Chartered Accountants LLP Firm Registration No.: 117364W/W100739
- · Outgoing auditors S R B C & CO LLP cease office upon completion of tenure at conclusion of FY2026-27 AGM
- · Appointment is subject to approval of the shareholders of the Company
- · NSE Code: SUNPHARMA; BSE Code: 524715
- · Company CIN: L24230GJ1993PLC019050
- · Anoop Deshpande ICSI Membership No.: A23983
30-10-2026
Alkem Laboratories disclosed that a US FDA inspection at its Mandva API manufacturing facility, conducted from 26th October 2026 to 30th October 2026, concluded with no Form 483 observations. The clean inspection outcome is a positive regulatory development for the company's API operations, though the filing contains no financial figures or period-over-period performance data.
- · Inspection was conducted over a five-day period from 26th October 2026 to 30th October 2026
- · Facility inspected is the Company's API manufacturing facility located at Mandva
- · Scrip Code: 539523; Scrip Symbol: ALKEM
- · Filing signed and digitally dated 30th October 2026 at 15:06:24 +05:30
30-10-2026
Cipla reported Q2 FY27 revenue of INR7,404 crores, up 4% QoQ, with EBITDA margin (ex-other income) at 18.7% (up 200 bps QoQ) and PAT of INR878 crores (11.9% of sales). One India grew 12% YoY, led by branded prescription (+15%) and chronic therapies, while North America revenue was $172 million (up $10 million QoQ) and EMEU $101 million. However, trade generics grew only mid-single digits YoY and South Africa reported a decline due to an accounting change and a lost tender, though a favorable court ruling may correct this.
- · Trade generics grew mid-single digits YoY, impacted by seasonality and cost factors.
- · South Africa reported a decline in primary sales due to an accounting change and a lost tender, though a favorable court ruling may correct this.
- · U.S. FDA issued 7 observations in Form 483 for the Pithampur facility; the company is working to resolve them.
- · The company maintains FY27 EBITDA margin guidance of 18.5% to 20% and U.S. exit run rate of $1 billion.
- · R&D guidance for FY27 is 6% to 7% of revenue.
- · Tax rate for full year expected to be 27% to 27.5%.
- · Generic Advair launch is expected in Q3 FY27, with revenue building in Q3 and Q4.
- · The company has 4 biosimilar programs under development and plans 45-50 U.S. filings over the next 3 years.
30-10-2026
Sun Pharmaceutical Industries Limited disclosed that the audio recording of its FY27 Q2 earnings call, held on 30 October 2026, is now available on the company's website. The filing is a routine Regulation 30 compliance intimation following the earlier 15 October 2026 earnings call notice, and contains no financial results, guidance, or performance data.
- · Earnings call audio recording file referenced as 'FY27-Q2-Earnings-Call-Recording-10047964.mp3'
- · Prior intimation regarding the earnings call was dated 15 October 2026
- · Scrip Symbol: SUNPHARMA on NSE; Scrip Code: 524715 on BSE
- · CIN: L24230GJ1993PLC019050
- · Company Secretary ICSI Membership No.: A23983
- · Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat
30-10-2026
Sun Pharmaceutical Industries announced that the U.S. FDA approved the supplemental Biologics License Application (sBLA) for ILUMYA® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis, expanding the IL-23 inhibitor beyond its 2018 moderate-to-severe plaque psoriasis indication. The approval is supported by the Phase 3 INSPIRE-1 and INSPIRE-2 studies, with no new safety signals identified. However, the filing contains no financial figures, revenue guidance, or period-over-period performance data, so the commercial impact of the label expansion cannot be quantified from this disclosure.
- · ILUMYA was originally FDA-approved in 2018 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
- · ILUMYA is an IL-23 inhibitor administered exclusively by a healthcare provider, positioning it for patients unable to self-administer treatment
- · ILUMYA is also approved for moderate-to-severe plaque psoriasis in India, Australia, Canada, China and Japan, and marketed as ILUMETRI® in Europe by Almirall
- · ILUMYA is described as the first biologic to earn the National Psoriasis Foundation (NPF) Seal of Recognition
- · Most common adverse reactions: Plaque Psoriasis (≥1%) upper respiratory infections, injection site reactions, diarrhea; Psoriatic Arthritis (≥3%) upper respiratory tract infections and COVID-19
- · ILUMYA may increase infection risk; patients should be evaluated for tuberculosis prior to initiating treatment
- · Filing was intimated under Regulation 30 of SEBI LODR Regulations, 2015, to NSE (Scrip Symbol: SUNPHARMA) and BSE (Scrip Code: 524715)
- · Registered office: SPARC, Tandalja, Vadodara – 390 012, Gujarat; corporate office at Sun House, Goregaon (E), Mumbai – 400 063
30-10-2026
Max Healthcare Institute Limited's Nomination and Remuneration Committee approved the grant of 95,000 stock options to eligible employees under the MHIL ESOP - 2022 scheme on October 30, 2026, at an exercise price of ₹800 per option. Each option converts into one fully paid-up equity share of face value ₹10, with vesting between 1 and 5 years from grant and an exercise window of 3 years from each vesting date. The grant represents a routine employee compensation disclosure under Regulation 30 of SEBI LODR, with no financial performance metrics reported.
- · Vesting schedule: not earlier than 1 year and not later than 5 years from the date of grant, subject to pre-vesting conditions
- · Options may be exercised within 3 years from the respective date of vesting
- · Scheme is in compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
- · NRC meeting commenced at 10.31 am IST and concluded at 10.48 am IST on October 30, 2026
- · NSE symbol: MAXHEALTH; BSE Scrip Code: 543220
- · Disclosure hosted on company website www.maxhealthcare.in
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 15 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: BSE Pharma Sector Regulatory Filings
🇮🇳 More from India
View all →October 23, 2026
India Pre-Market Regulatory Roundup — October 23, 2026
India Pre-Market Regulatory Roundup
October 23, 2026
India Quarterly Results BSE NSE Announcements — October 23, 2026
India Quarterly Results BSE NSE Announcements
October 23, 2026
India Upcoming Corporate Actions BSE NSE — October 23, 2026
India Upcoming Corporate Actions BSE NSE
October 23, 2026
India Merger Acquisition MCA Regulatory Filings — October 23, 2026
India Merger Acquisition MCA Regulatory Filings